is...optimistic for the future of CNS conditions thanks to Anavex Life Sciences.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
And which vaccine(s) did they receive?
Though, of course, it still shows how vital a therapeutic (Brilacidin) is in the grand scheme of things.
Antifungal. Antibacterial. Antiviral. Antinflammatory.
Good call.
Just a player out there with more dry powder than me.
GLTAL!!!
Wish it could have been named ‘Penetratesevir’ rather than Brilacidin.
Just spitballin’...
Like I said...that’s a substantial position taken at roughly $7-9 million depending on what lots were purchased at what time and the address in question being listed as a pizza/ TDAmeritrade building is odd. John Miller is a pretty generic name as well. You got some better ideas?
What if...
....”Kips Bay Select LP” is simply a shell corporation allowing a larger entity, e.g. BlackRock, to amass a position while the stock is under $5/share?
https://www.investopedia.com/terms/s/shellcorporation.asp
20,978,229 shares of Common Stock Class A is a substantial position.
Did Gilead create an alias to allow for a significant buy-in with IPIX (for Brilacidin) that could be used synergistically with remdesivir in the not-too-distant future?
Given the cost of remdesivir, I wonder what pricing of brilacidin would be?
https://www.ajmc.com/view/gilead-sciences-sets-us-price-for-covid19-drug-at-2340-to-3120-based-on-insurance
“ Gilead Sciences Monday set the price for remdesivir, its antiviral drug that can shorten hospitalization stays for individuals ill with coronavirus disease 2019 (COVID-19) from SARS-CoV-2 infection, at $520 a vial, or $3120 per patient for a typical treatment course, for those with private insurance.
The price those not covered by private insurance will be $390 per vial. A treatment course is 6 vials. The FDA approved the drug for emergency use in some patients and the company has applied for full approval.
The Institute for Clinical and Economic Review (ICER) last week said remdesivir would be cost-effective at a price range of $4580 to $5080 if it saved lives. However, news that an inexpensive steroid, dexamethasone, which does not have a patent, improves survival means remdesivir should be priced between $2520 and $2800, ICER said.”
Big Picture hypothesis...
When the RBL tested Brilacidin (in vitro and in vero) and had such outstanding results against one strain of novel coronavirus, what OTHER viral, bacterial, and fungal arrangements did they start thinking about for future testing?
Brilacidin is NOT a one trick pony. It has broad spectrum applications. So many people are zeroed in on COVID that they don’t realize Brilacidin is representative of an entire new class of drugs beyond just antibiotics.
Consider the findings thus far...
https://www.biorxiv.org/content/10.1101/2020.10.29.352450v1.full
Sounds like either Pfizer or Gilead could sure use a “win”...
2017 history lesson
https://www.biospace.com/article/anonymous-short-trader-attacks-cellceutix-again-/
When an anonymous slug bashes the company with unfounded crap and tanks the share price because it is a threat to other pharmaceutical companies with compounds such as Brilacidin that have enormous potential, yeah, it’s a very freakin’ serious deal.
Could Brilacidin have already been available PRIOR to the pandemic had the company not been savaged by some anonymous hack? Yes.
$3 minimum...
Please refer to Cellceutix share prices prior to being sabotaged by Mako. Thanks.
Are you ready for the summer?
Are you ready for the vaccine?
https://www.nytimes.com/2021/02/03/health/vaccine-novavax.html
When BlackRock AND company leadership are buying...
...well? That’s a pretty damn bullish signal.
Looking forward to all the possibilities for Technosphere applications.
Also, at the gut level, wondering whether UTHR might just wholly acquire MNKD. Maybe they’re just giving present managers a chance to prove themselves?
Here’s hoping Al’s dream comes true.
https://aemf.org/item/story-of-alfred-mann/
Solid visionary ahead of his time in many regards.
Thanks abew4me! Good things happening.
Key takeaway...
Returning normal mitochondrial functions (homeostasis) to cells. Works across a range of maladies because they share protein misfolding as a trait. 2-73 and 3-71 assist in correcting the misfolding of proteins at the cellular level.
If anyone can make that description any clearer, I thank you in advance. GLTA!
Reuters: Novavax submits COVID-19 vaccine for authorization in Canada
https://www.reuters.com/article/health-coronavirus-novavax-canada/novavax-submits-covid-19-vaccine-for-authorization-in-canada-idUSL4N2K74FD
(not sure why this didn’t make it up top into the headlines, but there’ll be a lot more good news coming too.
BlackRock upped their position.
Might have a lot to do with UTHR and MNKD partnership advancing inhaled delivery of Tyvaso® (treprostinil).
(Estimates of the total surface area of lungs vary from 50 to 75 square meters. Any patient requiring medicine to be delivered ASAP via MannKind’s Technosphere system stands to benefit from future developments.)
https://finance.yahoo.com/news/indias-serum-institute-seeks-approval-043937565.html
The news just keeps getting better.
Comparison...
NVAX 15.1B Market Cap and Shares Outstanding 67.3M
vs.
MRNA 68.6B Market Cap and Shares Outstanding 395.7M
I’d say our company is still VERY undervalued.
Purely hypothetical thought on my part...
What if Novavax bought out IPIX to fill in the therapeutic gaps?
Then it would be the vaccine and therapeutic powerhouse.
Guess that Phase II will be some make-or-break mamma jamma mojo!
Stoked to see the results.
When Novavax brings the rest of its pipeline to bear after Cov2373, yes.
Can’t wait to be injected with their vaccines!
LOL...yes indeed. Surrounded by gamers!
Will be cool to see how the U.S., South Africa, and Mexico results turned out too!
Fortnite = 14 days...
https://www.pharmaceutical-technology.com/comment/novavaxs-south-african-phase-iib-covid-19-vaccine-trial-likely-to-reveal-results-within-next-fortnight-source-says/
13 January 2021 (Last Updated January 13th, 2021 09:08)
Spread it on.
True enough.
Might be in the family.
Almost makes me want to start a page on reddit about AVXL being undervalued.
Yeah 10. Copy that.
Colchicine eh?
“ 12.1.6 Ingestion Symptoms
Gastrointestinal phase: Nausea; loss of appetite (anorexia); abdominal pain; vomiting (emesis); profuse, watery, and bloody diarrhea; joint pain; generalized weakness; fever; rashes; and hypovolemic shock.
Multiple system organ failure phase: Hypovolemic shock due to extreme vascular damage and fluid loss through the GI tract may result in death; kidney damage resulting in low urine output and bloody urine; swollen, tender liver with elevated liver enzymes; low white blood cell counts (persisting for several days); other blood (hematologic) manifestations including bone marrow depression, low platelets, and anemia; muscular weakness; ascending paralysis that may result in respiratory failure; and loss of deep tendon reflexes. The patient/victim usually remains conscious but exhibits mental confusion or delirium and seizures. Pediatric patient/victims may experience hallucinations.”
Selectivity Index...
“The selectivity index (SI) is a ratio that measures the window between cytotoxicity and antiviral activity by dividing the given AVA value into the TOX value (AVA/TOX). The higher the SI ratio, the theoretically more effective and safe a drug would be during in vivo treatment for a given viral infection. The ideal drug would be cytotoxic only at very high concentrations and have antiviral activity at very low concentrations, thus yielding a high SI value (high AVA/low TOX) and thereby able to eliminate the target virus at concentrations well below its cytotoxic concentration. The selectivity index of a compound is a widely accepted parameter used to express a compound’s in vitro efficacy in the inhibition of virus replication.”
While many are focused on a near-term coronavirus therapy, please keep in mind that Brilacidin’s capabilities would likely extend to other infections as well. Brilacidin has displayed anti-fungal, antibiotic, and antiviral properties. The clock is ticking.
HDMP (Human Defensin Mimetic Proteins) for the win.
Primarily: Easily moved without cold supply chain logistics.
Secondarily: Formulated to account for genetic drift and address variants.
Tertiary bonus: Best adjuvant in the industry. Matrix-M.
Novavax might not have rushed its vaccine like the others, but it will be the game changer globally.
Hopefully by this time next year I’ll have received all 3 shots: NVX-CoV2373, NanoFlu, and RSV-F.
Thorough respiratory protection.
https://finance.yahoo.com/news/neutrisci-provides-washington-state-approval-163000319.html
Doesn’t look as if the news feed is being updated regularly.
Seems Anavex could kick financial butt simply by rolling out blarcamesine as a sleeping aid.
The added benefit would be improved mitochondrial function. And a paucity of side effects.
“The first warning came a dozen years ago, when the Food and Drug Administration accused the drug company AstraZeneca of “false or misleading” information about health risks in the marketing material for its blockbuster medication Seroquel, an antipsychotic developed to treat schizophrenia but increasingly prescribed “off label” for insomnia.”
Good stuff. Thanks polarbear77.
Scrolled through but didn’t see any related post.
NVAX will be picking up the slack for Donny’s sabotage...
https://www.nytimes.com/2020/12/07/us/trump-covid-vaccine-pfizer.html
“with Expanding Claims“
Outstanding.
https://en.wikipedia.org/wiki/Treprostinil
Long time comin’.
More formulations ahead.
Lucky ba**ard!
Pierre Briançon...I envy you and salute you good sir!
Therapeutic vs. Vaccine
Brilacidin is being evaluated as a therapeutic, NOT a vaccine.
The kicker is that, given Brilacidin’s mechanisms (PLURAL) of action, it’s effectiveness is not limited to one novel coronavirus.
Though the news cycle might be overshadowing it, MRSA is still a defined threat, and Brilacidin has the potential to change that, and many other games going forward.
https://www.researchgate.net/publication/281335979_Brilacidin_A_Novel_Antibiotic_Designed_to_Prevent_MRSA